A detailed history of Vanguard Group Inc transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Vanguard Group Inc holds 17,676,767 shares of BCRX stock, worth $107 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,676,767
Previous 17,763,720 0.49%
Holding current value
$107 Million
Previous $106 Million 15.61%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$4.89 - $7.65 $425,200 - $665,190
-86,953 Reduced 0.49%
17,676,767 $89.8 Million
Q4 2023

Feb 14, 2024

BUY
$4.98 - $6.77 $11.8 Million - $16.1 Million
2,371,401 Added 15.41%
17,763,720 $106 Million
Q3 2023

Nov 14, 2023

BUY
$6.71 - $7.92 $2.03 Million - $2.39 Million
302,270 Added 2.0%
15,392,319 $109 Million
Q2 2023

Aug 14, 2023

BUY
$6.96 - $8.81 $1.84 Million - $2.33 Million
263,936 Added 1.78%
15,090,049 $106 Million
Q1 2023

May 15, 2023

BUY
$7.94 - $11.84 $4.94 Million - $7.36 Million
621,718 Added 4.38%
14,826,113 $124 Million
Q4 2022

Feb 10, 2023

BUY
$10.5 - $14.2 $3.84 Million - $5.19 Million
365,783 Added 2.64%
14,204,395 $163 Million
Q3 2022

Nov 14, 2022

BUY
$10.79 - $14.81 $306,856 - $421,181
28,439 Added 0.21%
13,838,612 $174 Million
Q2 2022

Aug 12, 2022

BUY
$7.89 - $17.88 $4.76 Million - $10.8 Million
603,133 Added 4.57%
13,810,173 $146 Million
Q1 2022

May 13, 2022

BUY
$11.56 - $19.76 $43.9 Million - $75 Million
3,794,135 Added 40.31%
13,207,040 $215 Million
Q4 2021

Feb 14, 2022

BUY
$11.18 - $15.46 $400,881 - $554,349
35,857 Added 0.38%
9,412,905 $130 Million
Q3 2021

Nov 12, 2021

BUY
$14.21 - $17.65 $1.03 Million - $1.28 Million
72,505 Added 0.78%
9,377,048 $135 Million
Q2 2021

Aug 13, 2021

BUY
$9.5 - $17.24 $88.4 Million - $160 Million
9,304,543 New
9,304,543 $147 Million

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.13B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.